This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and randomized to a screening program using PSA, a biomarker test and MRI; (ii) invited and randomized to a single PSA test with prostate biopsies followed by opportunistic testing and (iii) population controls. Mortality is verified through register data, disease verification is made through in-study biopsy results and registry data.

Eligible participants:

-Men eligible for the longterm f/u-study arms (experimental and control) are participants in the STHLM3MRI trial.

Inclusion Criteria:

• Men age 50-74 years without prior diagnosis of prostate cancer (ICD-9 C61).
• Permanent postal address in Stockholm
• Not a previous participant in the Stockholm3 study (2012-2014)

Exclusion Criteria:

• Severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia
• Contraindications for magnetic resonance imaging (MRI) eg pacemaker, magnetic cerebral clips, cochlear implants or severe claustrophobia.
• Men with a previous prostate biopsy the preceding 60 days before invitation.

Individual participant data underlying the results reported in this project will be available after deidentification, together with the study protocol, statistical analysis plan, and analytic code. Data will be made available to researchers who provide a methodologically robust proposal, in which the aims are relevant and clear. Proposals can be submitted up to 24 months after publication of the first main article of the project and should be directed to tobias.nordstrom@ki.se. Only proposals with ethical approval will be granted access to the data.

24 months from publication of first main manuscript of the project

Outcomes are verified through national registers